{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-25-000009","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2025-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.543226+00:00","generated_at":"2026-05-26T12:15:08.418987+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Krystal Biotech Q4 revenue $91.1M (+116% YoY); net income $45.5M; FY revenue $290.5M","bullets":["Q4 2024 product revenue $91.1M (+116% YoY); full year $290.5M (+473% vs 2023).","Q4 2024 net income $45.5M ($1.58 basic EPS) vs $8.7M ($0.31) in Q4 2023.","Cash, cash eq & investments $749.6M as of Dec 31, 2024.","Pipeline: KB707 solid tumors ORR 27%; KB408 AATD interim positive; CFF sanctioned KB407 CF study.","FY2025 non-GAAP R&D+SG&A guidance $150-175M."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-25-000009","json":"https://secwatch.observer/filing/0001711279-25-000009.json","markdown":"https://secwatch.observer/filing/0001711279-25-000009.md","text":"https://secwatch.observer/filing/0001711279-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000009/0001711279-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000009/krys-20250219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T12:15:08.418987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}